Aroa Biosurgery Limited (ARX.AX) Stock Analysis & Winston Score

Aroa Biosurgery is a New Zealand-based medical device company that makes soft tissue repair products used in surgeries. Its core technology is a material called Myriad Matrix, derived from sheep stomach lining, which helps the body rebuild damaged tissue. Surgeons and hospitals — mainly in the United States — use Aroa's products to treat complex wounds and repair soft tissue after surgery. The company earns revenue by selling its products directly and through a distribution partnership with Tela Bio, a US-based partner that sells Aroa's materials under its own brand. Aroa operates primarily in the US market, which drives the large majority of its sales, and its high gross margin of around 86% reflects the premium nature of its biological materials. The key growth driver is expanding its US commercial reach and broadening its product range, while the main risk is heavy dependence on Tela Bio as a distribution partner — any change to that relationship could significantly impact revenue.